screening

screening

screening

A menstrual blood test detects the human papillomavirus (HPV) and could serve as an alternative in cervical cancer screening

A team in China has studied the ability of a test to detect the human papillomavirus (HPV)—responsible for the vast majority of cervical cancers—in menstrual blood from more than 3,000 women. The results indicate that the test is comparable to current screening performed in medical offices. According to the researchers, “Using menstrual blood for HPV testing is practical and non-invasive, allowing women to collect samples at home and thus potentially offering a practical way to expand access to screening.” The study is published in The BMJ. 

0

An AI tool improves cancer screening in dense breasts

An artificial intelligence (AI) model trained on over 400,000 mammograms and analyzed in a separate sample of over 240,000 improved cancer risk prediction in cases of dense breasts, which are more common in young women or those with a low body mass index. This is an important factor in screening, especially because it can hinder tumor detection. The results are presented as an abstract, not yet peer-reviewed, at the annual meeting of the Radiological Society of North America.

0

Researchers analyse the impact of colorectal cancer screening campaigns on people aged 45 to 49

In the US, the incidence of colorectal cancer increased in people aged 45-49 years in the period 2019-2022, after advancing the screening age from 50 to 45 years, according to a study published in JAMA. The use of mailed faecal tests made it possible to reach people in this age group, without affecting screening rates in people over 50, says another paper published in the same journal.

0

Genetic testing would improve prostate cancer screening, according to a study

One of the problems with prostate cancer screening is that it results in a high rate of false positives, that is, erroneous diagnoses in people without the disease. A study in the UK has applied a genetic test to more than 6,000 people aged between 55 and 69, analysing 130 variants related to this tumour, which allows a ‘risk score’ to be calculated. According to the results, which are published in the journal NEJM, the test detected the disease more likely in people with higher values than traditional screening.

0

Newborn genetic screening outperforms standard screening in detecting more serious diseases, preliminary study finds

Early results from a study of newborn screening methods show that DNA analysis detects many more serious preventable or treatable diseases than standard newborn screening. The study, published today in the journal JAMA, is one of the first large-scale studies in the world to use genome sequencing as a method of newborn screening and is the first to publish preliminary results. 

0

Clinical trial examines efficacy of prostate cancer screening with MRI to reduce overdiagnosis

Prostate cancer screening tests using PSA (Prostate Specific Antigen) are associated with overdiagnosis, which calls into question their use. A clinical trial in men aged 50-60 years published in the journal NEJM has studied the possibility of adding an MRI test in those with an elevated PSA level and dispensing with biopsy if imaging finds no suspicious lesions. The results indicate that the procedure avoids more than half of clinically irrelevant cancer diagnoses that would not need treatment and only slightly increases the risk of failing to identify those that may become incurable. The authors recommend, on the basis of the study, to review the recommendations for such screening.

0

Reaction: new tests for colorectal cancer screening by detecting DNA in stool and blood evaluated

Two studies published in the New England Journal of Medicine evaluate colorectal cancer screening tests that could be alternatives to the existing faecal immunochemical test (FIT), which detects occult blood in stool. The first study uses a new generation test that detects DNA in stool and has a higher sensitivity than FIT, 93.9% for colorectal cancer and 90.6% for advanced neoplasia (tumour formation). The second uses a blood-based DNA detection test with a sensitivity of 83% for colorectal cancer and 90% for advanced neoplasia.   

0